Navigation Links
Caliper Life Sciences and DiscoveRx Announce Availability of PathHunter eXpress Reagents for GPCR Assays
Date:10/7/2008

- PathHunter eXpress Kits Combined with LabChip Microfluidic Instruments Provide a Comprehensive, High Quality, Easy-to-Use GPCR Assay Solution -

HOPKINTON, Mass. and FREMONT, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) and DiscoveRx, today announced the commercial availability of PathHunter(TM) eXpress Beta-Arrestin kits for use with Caliper's LabChip(R) 3000 and EZ Reader(TM) platforms to conduct cellular G protein-coupled receptor (GPCR) assays. This milestone is part of the collaboration between Caliper and DiscoveRx, announced in May 2008, to provide a powerful and comprehensive suite of solutions to assist pharmaceutical and biotechnology researchers in more efficiently discovering new drugs.

"This joint solution enables researchers to quickly assess potency and potential side effects of new drug candidates in a cellular environment, which accelerates overall drug discovery programs," said Nate Cosper, Director of Marketing at Caliper Life Sciences. "Achievement of this commercial milestone underscores Caliper's commitment to partnering with leading technology companies like DiscoveRx to develop innovative solutions that provide higher quality and more reproducible data, improve scientific workflows and enable novel research approaches."

Caliper's LabChip 3000 and EZ Reader platforms, a suite of instruments for screening and profiling potential drug candidates, utilize microfluidic separation and direct detection of both substrates and products to generate high quality, reproducible data to qualify potential lead candidates. Caliper provides researchers in neuroscience, cardiovascular, and inflammation therapeutic areas with platforms and services for target validation, receptor screening, side effect profiling, functional cellular assays, in vivo efficacy studies using IVIS technology, and in vivo pharmacodynamic analysis.

"PathHunter eXpress Beta-Arrestin kits for use with Caliper's LabChip instruments contain everything needed to perform screening or profiling experiments: cells, detection reagents, media and plates. The workflow improvements inherent to this complete solution for live-cell GPCR experiments enables scientists to spend more of their time designing better and safer drugs," said Sailaja Kuchibhatla, Senior Vice President of Business Development at DiscoveRx. "Today's announcement further signifies the momentum generated by our partnership with Caliper and the relationships they are helping us develop with customers in secondary screening and profiling laboratories."

About DiscoveRx Inc.

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of Beta-Galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. For more information on DiscoveRx products, please visit http://www.discoverx.com.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

Caliper, LabChip, and EZ Reader are trademarks of Caliper Life Sciences, Inc.

DiscoveRx and PathHunter are trademarks of DiscoveRx Corporation.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences to Present at UBS Global Life Sciences Conference
2. Caliper Launches Small Animal Molecular Imaging System Enabling Real-Time Video Observation
3. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
4. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
5. Caliper Life Sciences Reports Second Quarter 2008 Results
6. Caliper Life Sciences Second Quarter 2008 Financial Results Conference Call Notice
7. Caliper Life Sciences Added to Russell 3000(R) Index
8. Caliper Life Sciences to Present at Deutsche Banks 33rd Annual Health Care Conference
9. Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
10. Caliper Life Sciences Reports West Coast Consolidation of Operations
11. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... -- VWR Corporation (NASDAQ: VWR), the leading global independent provider of ... reported its financial results for the fourth quarter and full ... 4Q16 record quarterly net sales of $1.13 billion, ... 4Q16 EMEA-APAC segment net sales ... Americas net sales increased 2.5%, or down 0.9% on an ...
(Date:2/23/2017)... 2017 ... share data, unaudited)Three Months Ended December 31,Twelve Months Ended ... $           ... 89026%Aldurazyme Net Product Revenue 3539(10)%9498(4)%Kuvan ... Product Revenue  756025%297303(2)%Vimizim Net Product ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
Breaking Biology Technology:
(Date:2/8/2017)... Feb. 7, 2017 The biometrics market ... the confluence of organizations, desires to better authenticate ... systems (password and challenge questions), biometrics is quickly ... systems. The market is driven by use cases, ... consumer and enterprise uses cases, with consumer-facing use ...
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
Breaking Biology News(10 mins):